Levosimendan Reig Jofre (Levosimendan)

Levosimendan binds to troponin C, increasing the sensitivity of the contractile proteins to calcium, which enhances myocardial contractility. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and lowering afterload without a large rise in intracellular calcium.

The dosing regimen for Levosimendan Reig Jofre is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. The product is supplied as an intravenous solution that is administered under continuous hemodynamic monitoring.

Safety data for Levosimendan in pregnancy and lactation are limited. The drug should be avoided during pregnancy and breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant, and only under specialist supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Compared with traditional inotropes such as dobutamine, Levosimendan increases contractility without a large rise in intracellular calcium, potentially reducing the risk of calcium‑mediated arrhythmias. Unlike phosphodiesterase inhibitors like milrinone, it also provides vasodilation through potassium‑channel activation, offering a dual hemodynamic benefit.

Levosimendan should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The solution should be kept in its original packaging until use, and any unused portion should be discarded according to local regulations.

Levosimendan is given as an intravenous infusion. After reconstitution according to the label, the infusion is started under continuous cardiac monitoring, typically with an initial loading dose followed by a maintenance infusion, as directed by the treating physician.

The most serious adverse events include severe hypotension, life‑threatening arrhythmias such as ventricular tachycardia, myocardial ischemia, and rare anaphylactic reactions. Prompt recognition and management of these events are essential during therapy.

Levosimendan is contraindicated in patients with severe uncontrolled hypotension, obstructive cardiac lesions (e.g., severe aortic stenosis), or known hypersensitivity to the drug. Caution is also advised in individuals with significant hepatic or renal impairment, and it should be avoided in pregnancy unless absolutely necessary.